Home>>Signaling Pathways>> Cardiovascular>> Myocardial Infarction>>Examorelin (Hexarelin)

Examorelin (Hexarelin) Sale

(Synonyms: 海沙瑞林) 目录号 : GC32451

A peptide agonist of GHS-R

Examorelin (Hexarelin) Chemical Structure

Cas No.:140703-51-1

规格 价格 库存 购买数量
1mg
¥803.00
现货
5mg
¥1,607.00
现货
10mg
¥2,053.00
现货
25mg
¥4,106.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Hexarelin is a synthetic hexapeptide agonist of the growth hormone secretagogue receptor (GHS-R).1,2 It selectively binds to GHS-R over CD36 (IC50s = 15.9 and 2,080 nM, respectively).1 Hexarelin (300 ?g/kg, s.c.) increases plasma growth hormone levels in neonatal rats.2 It also improves left ventricular function and reduces fibrosis in a mouse model of myocardial ischemia induced by transient ligation of the left descending coronary artery (LAD) when administered at a dose of 0.3 mg/kg per day.3

1.Proulx, C., Picard, ?., Boeglin, D., et al.Azapeptide analogues of the growth hormone releasing peptide 6 as cluster of differentiation 36 receptor ligands with reduced affinity for the growth hormone secretagogue receptor 1aJ. Med. Chem.55(14)502-511(2012) 2.Guerlavais, V., Boeglin, D., Mousseaux, D., et al.New active series of growth hormone secretagoguesJ. Med. Chem.46(7)1191-1203(2003) 3.McDonald, H., Peart, J., Kurniawan, N.D., et al.Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusionBiomed. Pharmacother.127110165(2020)

Chemical Properties

Cas No. 140703-51-1 SDF
别名 海沙瑞林
Canonical SMILES His-{d-2-ME-Trp}-Ala-Trp-{d-Phe}-Lys-NH2
分子式 C47H58N12O6 分子量 887.04
溶解度 DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 10 mg/ml 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.1273 mL 5.6367 mL 11.2734 mL
5 mM 0.2255 mL 1.1273 mL 2.2547 mL
10 mM 0.1127 mL 0.5637 mL 1.1273 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Gateways to clinical trials

Methods Find Exp Clin Pharmacol 2002 Nov;24(9):615-43.PMID:12616707doi

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, adalimumab, adefovir dipivoxil, AdGVVEGF121.10, anastrozole, anecortave acetate, aripiprazole, asulacrine isethionate, atazanavir, ATL-962, 16-Aza-epothilone B; Bevacizumab, bicalutamide, blonanserin, BMS-188667, bosentan; Celecoxib, celmoleukin, cetuximab, cilomilast, cinacalcet hydrochloride, CNTF(Ax15), colesevelam hydrochloride; Daclizumab, delavirdine mesilate, desogestrel, desoxyepothilone B, dexmethylphenidate hydrochloride, duloxetine hydrochloride; Ecogramostim, emtricitabine, epalrestat, escitalopram oxalate, Examorelin, exendin-4, ezetimibe; Fidarestat, frovatriptan; HIV-1 Immunogen; Iloperidone, insulin detemir, insulin lispro, irinotecan hydrochloride; Keratinocyte growth factor; Lasofoxifene tartrate, levetiracetam, levormeloxifene, levosimendan, lumiracoxib, LY-307161 SR; Memantine hydrochloride, MEN-10755, metformin hydrochloride, metreleptin, motexafin gadolinium; Naratriptan hydrochloride, natalizumab, nesiritide, nicotine, NN-2211, NN-414; Olanzapine, omalizumab; Pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, pimecrolimus, pirfenidone, pramlintide acetate prasterone, pregabalin; Quetiapine fumarate; Rabeprazole sodium, raloxifene hydrochloride, raltitrexed, rDNA insulin, rFGF-2, risedronate sodium, rofecoxib, roflumilast, rosiglitazone maleate; SN-22995; Tacrolimus, tadalafil, tegaserod maleate, tiotropium bromide, tomoxetine hydrochloride, trastuzumab, trimegestone; Voglibose, Voriconazole; Ziprasidone hydrochloride.

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study

Heliyon 2020 Jul 23;6(7):e04502.PMID:32754651DOI:10.1016/j.heliyon.2020.e04502.

The outbreak of SARS-CoV-2 in December 2019 in China subsequently lead to a pandemic. Lack of vaccine and specific anti-viral drugs started a global health disaster. For a sustained control and protection, development of potential anti-viral drugs is one of the targeted approach. Although, designing and developing a panel of new drugs molecules are always encouraged. However, in the current emergency, drug repurposing study is one of the most effective and fast track option. The crystal structure of a SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) RNA Dependent RNA Polymerase (RdRp) has recently been deciphered through X-ray crystallography. The single-chain of core RNA Dependent RNA Polymerase relies on virus-encoded cofactors nsp7 and two units of nsp8 for its optimum function. This study explored the FDA approved database of 7922 molecules and screened against the core polymerase along with cofactors. Here we report a panel of FDA approved drugs that show substantial interactions with key amino acid residues of the active site. Interestingly, some of the identified drugs (Ornipressin, Lypressin, Examorelin, Polymyxin B1) bind strongly within the binding pockets of both forms of RdRp. Besides, we found strong candidates for the complex form as well which include Nacortocin, Cistinexine, Cisatracurium (among others). These drugs have the potential to be considered while contriving therapeutic options.